AbbVie and Abbott-backed biotechnology developer AuraSense closed the $13.6m first tranche of the round in June last year.
US-based biotechnology company AuraSense Therapeutics, previously backed by healthcare company Abbott Laboratories and biopharmaceutical company AbbVie, has extended its series C round to $18m.
The round initially closed at $13.6m in June 2014, and included Rathmann Family Foundation and private investors Bill Gates, Patrick Ryan, David Walt, Boon Hwee Koh and Craig Mundie. AuraSense has not disclosed which investors have backed the series C extension.
AuraSense develops therapies based on its spherical nucleic acid technology to treat diseases that have…
